BioCentury
ARTICLE | Finance

Arch, Cormorant return to lead $200M megaround for Erasca

April 28, 2020 1:23 AM UTC

After adding over a half dozen pharma veterans to its R&D advisory board and advancing its cancer pipeline toward the clinic, Erasca has raised one of the year’s two largest venture rounds.

Arch Venture Partners and Cormorant Asset Management co-led San Diego-based Erasca Inc.’s $200 million series B round. The firms were joined by new investors EDBI, Invus, Terra Magnum Capital Partners and undisclosed other private and strategic investors, as well as existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners...